Article
Rilpivirine versus efavirenz with two background nucleoside or nucleotide reverse transcriptase inhibitors in treatment-naive adults infected with HIV-1 (THRIVE): a phase 3, randomised, non-inferiority trial.
Lancet (London, England) - 16 Jul 2011
Cohen Calvin J, Andrade-Villanueva Jaime, Clotet Bonaventura, Fourie Jan, Johnson Margaret A, Ruxrungtham Kiat, Wu Hao, Zorrilla Carmen, Crauwels Herta, Rimsky Laurence T, Vanveggel Simon, Boven Katia
Abstract excerpt
BACKGROUND: The non-nucleoside reverse transcriptase inhibitor (NNRTI), rilpivirine (TMC278; Tibotec Pharmaceuticals, County Cork, Ireland), had equivalent sustained efficacy to efavirenz in a phase 2b trial in treatment-naive patients infected with HIV-1, but fewer adverse events. We aimed to assess non-inferiority of rilpivirine to efavirenz in a phase 3 trial with common background nucleoside or nucleotide...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.